| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5890468 | Bone | 2014 | 7 Pages |
Abstract
In postmenopausal women who were suboptimally adherent to alendronate therapy, transitioning to denosumab was well tolerated and more effective than risedronate in increasing BMD and reducing bone turnover.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
C. Roux, L.C. Hofbauer, P.R. Ho, J.D. Wark, M.C. Zillikens, A. Fahrleitner-Pammer, F. Hawkins, M. Micaelo, S. Minisola, N. Papaioannou, M. Stone, I. Ferreira, S. Siddhanti, R.B. Wagman, J.P. Brown,